TECH Add to watchlist
$58.49 0.17 (-0.29%)
After Hours: $58.49 +0.00 (+0.00%)
Last updated: Apr 15, 2026 21:11
52-Week Range
$58.49
$46.01 $58.49 $72.16

Fundamentals Overview

Bio-Techne Corporation is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 113.2 P/B 4.53 P/S 7.53

Intrinsic value (DCF)

-62.5% downside vs price

Profitability

Net margin 6.7%

Risk (Beta)

1.49 — higher vol

Earnings & growth

EPS $0.52 Rev +3.3% Profit -0.5% vs prior qtr

BullzEye Analysis

Our composite tilts Sell on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Sell — 79% confidence Risk: High Volatility — Beta 1.49. Consider smaller position size due to higher beta.

Supporting (Buy):

Analyst grade: B-

Pressures (Sell):

DCF 62.5% downside vs price · Sentiment weakening (4 downgrades) · 3M vs S&P 500: -12.8% · 3M vs Healthcare sector: -6% · Beta 1.49 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$9.15B
P/E (TTM)
113.22
EPS (TTM)
$0.52
Dividend Yield
0.55%
52-Week Range
$46.01 - $72.16
Volume vs Avg
N/A
Beta
1.49

About

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibod...
Sector: Healthcare
Headquarters: US
Employees: 3,100
IPO Date: Feb 1989
Beta: 1.49 (More volatile than market)

Ratings & Grades at a Glance

Overall rating: B-. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 10, Hold: 2, In Line: 3, Neutral: 2, Outperform: 3, Overweight: 3, Sector Outperform: 2, Sector Perform: 3, Sector Weight: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $21.96; current price is $58.49. That’s a -62.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 113.22
DCF value (model) $21.96 (-62.5% vs price)
PEG (TTM) N/A
P/B (TTM) 4.53
P/S (TTM) 7.53
P/FCF (TTM) 41.03
Liquidity & enterprise
Current Ratio (TTM) 4.54
Quick Ratio (TTM) 3.08
Cash Ratio (TTM) 1.23
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 6.67%
Gross margin (TTM) 65.22%
Operating margin (TTM) 9.62%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for TECH.

Analyst Sentiment at a Glance

B- Sentiment Weakening
Buy 10Hold 2In Line 3Neutral 2Outperform 3Overweight 3Sector Outperform 2Sector Perform 3Sector Weight 2
2 upgrades, 4 downgrades
Price Target Consensus
Current $58.49
Median $69.00
Consensus $69.33
Low consensus $62.00
High consensus $79.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Evercore ISI Group maintain In Line In Line 2026-04-06
Wells Fargo maintain Overweight Overweight 2026-02-06
Citigroup maintain Buy Buy 2026-02-05
Stifel maintain Hold Hold 2026-02-05
TD Cowen maintain Buy Buy 2026-02-05
Evercore ISI Group maintain In Line In Line 2026-02-05
UBS maintain Buy Buy 2026-02-05
Evercore ISI Group downgrade Outperform In Line 2026-01-05
Argus Research maintain Buy Buy 2025-11-20
Wells Fargo maintain Overweight Overweight 2025-11-06
UBS maintain Buy Buy 2025-11-06
TD Cowen maintain Buy Buy 2025-10-14
Evercore ISI Group maintain Outperform Outperform 2025-10-07
RBC Capital upgrade Sector Perform Outperform 2025-09-03
Citigroup upgrade Neutral Buy 2025-08-21
RBC Capital maintain Sector Perform Sector Perform 2025-08-07
Scotiabank maintain Sector Outperform Sector Outperform 2025-07-11
Benchmark maintain Buy Buy 2025-06-05
UBS maintain Buy Buy 2025-05-09
Benchmark maintain Buy Buy 2025-05-08
Stifel maintain Hold Hold 2025-05-08
RBC Capital maintain Sector Perform Sector Perform 2025-05-08
Keybanc downgrade Overweight Sector Weight 2025-04-09
Keybanc downgrade Overweight Sector Weight 2025-04-08
Citigroup maintain Neutral Neutral 2025-03-04
Baird downgrade Outperform Neutral 2025-02-19
Baird maintain Outperform Outperform 2025-02-06
RBC Capital maintain Sector Perform Sector Perform 2025-02-06
Keybanc maintain Overweight Overweight 2025-02-06
Scotiabank maintain Sector Outperform Sector Outperform 2025-02-06